CMS delays requirement for drugmakers to offer multiple best prices for Medicaid value-based deals

Robert King | May 27, 2021

The Biden administration has delayed for six months the implementation of a Trump-era rule aimed at incentivizing the use of value-based drug price agreements in Medicaid.

The Centers for Medicare & Medicaid Services (CMS) released a proposed rule Wednesday that delays implementation of a requirement for manufacturers to report multiple best prices for a drug covered under Medicaid if the drugmaker is participating in a value-based purchasing arrangement.

The original version of the regulation, finalized on Dec. 31, 2020, implemented the requirement on Jan. 1, 2022, but the Biden administration wants to delay the deadline to July 1, 2022.

Source: Fierce Healthcare